STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Enliven Therapeutics reported that its targeted drug ELVN-001 induced molecular responses in nearly half of advanced leukemia patients.
- ELVN-001 achieved a major molecular response in 48% of chronic myeloid leukemia patients after a 24‑week, 80 mg once‑daily regimen.
- Patients treated earlier in their disease showed higher response rates than those treated later.
- The study results, released Thursday, were said to compare favorably with Novartis’s blockbuster CML therapy and a Merck‑acquired experimental drug.
Why it matters: The trial data give Enliven Therapeutics a tangible advantage, as the 48% major molecular response rate is comparable to the efficacy of Novartis’s leading CML drug and the Merck‑acquired experimental agent, providing clinicians with an additional proven option. The data also highlight higher response rates in patients treated earlier, underscoring the benefit of early intervention.
